Erythropoietin as a treatment of anemia in heart failure: Systematic review of randomized trials
- 31 May 2011
- journal article
- review article
- Published by Elsevier BV in American Heart Journal
- Vol. 161 (5), 822-831.e2
- https://doi.org/10.1016/j.ahj.2011.02.013
Abstract
No abstract availableThis publication has 41 references indexed in Scilit:
- Effects of eythropoietin administration on mitral regurgitation and left ventricular remodeling in heart failure patientsInternational Journal of Cardiology, 2010
- Secondary analysis of the CHOIR trial epoetin-α dose and achieved hemoglobin outcomesKidney International, 2008
- Effects of darbepoetin-alpha on quality of life and emotional stress in anemic patients with chronic heart failureEuropean Journal of Preventive Cardiology, 2008
- Effects of darbepoetin α on right and left ventricular systolic and diastolic function in anemic patients with chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathyAmerican Heart Journal, 2008
- Venous Thromboembolism and Mortality Associated With Recombinant Erythropoietin and Darbepoetin Administration for the Treatment of Cancer-Associated AnemiaJAMA, 2008
- Effects of β-erythropoietin treatment on left ventricular remodeling, systolic function, and B-type natriuretic peptide levels in patients with the cardiorenal anemia syndromeAmerican Heart Journal, 2007
- Emerging Role of Anemia in Heart FailureThe American Journal of Cardiology, 2007
- Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemiaAmerican Heart Journal, 2006
- The prognostic value of exercise capacity: A review of the literatureAmerican Heart Journal, 1991
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986